CAR-T对宫颈癌的干预
嵌合抗原受体修饰 T 细胞 (CAR-T 细胞) 治疗宫颈癌的多中心试验
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
研究概览
详细说明
Cervical cancer is a cancer arising from the cervix. Human papillomavirus (HPV) infection causes more than 90% of cases. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Worldwide, cervical cancer is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women. The treatment of cervical cancer consists of surgical intervention, radiation, chemotherapy and immunotherapy.
In this study, the participant's T-cells will be collected and modified. Then the modified T cells, called chimeric antigen receptor modified-T cells (CAR T) which can recognize specific molecules that are expressed on the surface of cervical cancer cells, are given back to the participant by intravenous infusion.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Guangdong
-
Shenzhen、Guangdong、中国、518000
- Shenzhen Geno-immune Medical Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients with stage III, IV or relapsed cervical cancer confirmed by histology and biopsy.
-
Age: ≥ 18 years and ≤ 70 years.
-
4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy.
-
Side Effects of Chemotherapy have subsided.
-
GD2, PSMA, Muc1, Mesothelin or other markers is expressed high (above 2+) in malignancy tissues by immuno-histochemical or flow cytometry.
-
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
-
Expected survival ≥ 12 weeks.
-
Initial hematopoietic reconstitution with
- neutrophils (ANC) ≥ 1×10^6/L;
- platelet (PLT) ≥ 1×10^8/L.
-
Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with
- serum creatinine ≤ 2×ULN;
- serum bilirubin ≤ 3×ULN;
- AST/ALT ≤ 2.5×ULN.
-
Oxygen saturation ≥ 90%.
-
Written, informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
-
Airway obstruction caused by tumor.
-
History of epilepsy or other central nervous system diseases.
-
Patients who require systemic corticosteroid or other immunosuppressive therapy.
-
History of prolonged or serious heart disease during QT.
-
history of serious cyclophosphamide toxicity.
-
Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.
-
Inadequate liver and renal function with
- serum creatinine > 1.5 mg/dl;
- serum (total) bilirubin > 2.0 mg/dl;
- AST & ALT > 3 x ULN.
-
Pregnant or lactating females.
-
Serious active infection during screening.
-
Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.
-
Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cervical cancer-specific CAR-T cells
Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells. |
1 infusion, for 1x10^6~1x10^7 cells/kg via IV |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety of CART cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events
大体时间:3 months
|
Physiological parameter (measuring cytokine response) |
3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Persistence and proliferation of CART cells in patients
大体时间:3 months
|
The expansion and functional persistence of CART cells in the peripheral blood of patients will be measured by qPCR on Day 7, 14, 21, 28, 60 and 90 after infusion. |
3 months
|
|
Anti-tumor effects
大体时间:1 year
|
Objective response, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. |
1 year
|
合作者和调查者
调查人员
- 首席研究员:Lung-Ji Chang, PhD、Shenzhen Geno-Immune Medical Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.